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Abstract
Background
Preventive chemotherapy and transmission control (PCT) by mass drug administration is
the cornerstone of the World Health Organization (WHO)’s policy to control soil-transmitted
helminthiases (STHs) caused by Ascaris lumbricoides (roundworm), Trichuris trichiura
(whipworm) and hookworm species (Necator americanus and Ancylostama duodenale)
which affect over 1 billion people globally. Despite consensus that drug efficacies should be
monitored for signs of decline that could jeopardise the effectiveness of PCT, systematic
monitoring and evaluation is seldom implemented. Drug trials mostly report aggregate effi-
cacies in groups of participants, but heterogeneities in design complicate classical meta-
analyses of these data. Individual participant data (IPD) permit more detailed analysis of
drug efficacies, offering increased sensitivity to identify atypical responses potentially
caused by emerging drug resistance.
Methodology
We performed a systematic literature review to identify studies concluding after 2000 that
collected IPD suitable for estimating drug efficacy against STH. We included studies that
administered a variety of anthelmintics with follow ups less than 60 days after treatment. We
estimated the number of IPD and extracted cohort- and study-level meta-data.
Principal findings
We estimate that there exist individual data on approximately 35,000 participants from 129
studies conducted in 39 countries, including 34 out of 103 countries where PCT is
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recommended. We find significant heterogeneity in diagnostic methods, times of outcome
assessment, and the reported measure of efficacy. We also quantify cohorts comprising
pre-school age children, pregnant women, and co-infected participants, including with HIV.
Conclusions
We argue that establishing a global IPD repository would improve the capacity to monitor
and evaluate the efficacy of anthelmintic drugs, respond to changes and safeguard the
ongoing effectiveness of PCT. Establishing a fair, transparent data governance policy will
be key for the engagement of the global STH community.
Author summary
Soil-transmitted helminthiases (STHs) caused by roundworm, whipworm or hookworm
affect over one billion of the world’s poorest people mostly living in low and middle
income countries, exerting a major health and economic toll. These infections are con-
trolled by regular mass drug distribution to affected populations. But with very few alter-
native medicines, the effectiveness of treatment programmes is vulnerable to the potential
emergence of drug resistance. Despite a recent scale-up of mass drug distribution, system-
atic monitoring and evaluation of the efficacy of treatment is too rarely undertaken and
our knowledge of how the drugs are performing is largely based on information from clin-
ical trials. However, the design and reporting of information from these trials is very vari-
able which makes it difficult to form a comprehensive picture of the status and trends in
drug efficacy. Here, we present a systematic review of published studies completed since
2000, characterise variation in their design, implementation and reporting and estimate
the abundance of individual participant data. We argue that the co-ordinated sharing of
these individual data would greatly increase the capacity of the global health community
to monitor effectively drug efficacy, to respond accordingly to changes, and thereby to
safeguard the effectiveness of STH control.
Introduction
Soil-transmitted helminthiases (STHs) are a group of intestinal nematode infections of
humans most commonly, though not exclusively, caused by the roundworm Ascaris lumbri-
coides, the whipworm Trichuris trichiura and the hookworm species (Necator americanus or
Ancylostoma duodenale). These infections place a heavy burden of disease on endemic regions,
mostly low and middle income countries (LMICs). An estimated 3.2 million years lived with
disability (YLDs) were caused by STHs in 2015, with 1.8 million attributed to hookworm infec-
tion [1] which is associated with intestinal blood loss, iron deficiency anaemia and protein
malnutrition [2]. Ascariasis is the most common STH with a global prevalence estimated at
over 760 million. Altogether, it is estimated that about 1.45 billion people—about 20% of the
world’s population—suffer from STHs [1].
Soil-transmitted helminthiases are treated and controlled predominantly using the benz-
imidazole drugs albendazole or mebendazole. The World Health Organization (WHO)
recommends giving single (400 mg for albendazole, 500 mg for mebendazole) doses of benz-
imidazoles to pre-school age children (pre-SAC) and school age children (SAC) in endemic
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communities (the latter defined as having20% overall prevalence) at least annually as part of
the preventive chemotherapy and transmission control (PCT) strategy delivered by mass drug
administration (MDA) [3]. This strategy is aimed at controlling and preventing morbidity
caused by STHs and, to meet this objective, the WHO has set 2020 treatment-coverage goals
for at-risk populations of 75% in pre-SAC and SAC [4]. These goals were endorsed at the 2012
London Declaration on Neglected Tropical Diseases (NTDs) [5] and have since driven a scale-
up in the global distribution of benzimidazoles. In 2015 alone, 572.7 million pre-SAC and SAC
were treated for STH infection, approximately 60% of the globally at-risk population requiring
preventive chemotherapy and a doubling in global treatment coverage since 2010 [6].
The scale-up of MDA towards the 2020 goals is projected to increase greatly the cost-effec-
tiveness of STH control [7]. However, the continuing effectiveness of PCT as a control strategy
depends on the enduring efficacy of the distributed drugs. There exist arguments both for and
against STH resistance to benzimidazoles emerging [8]. Arguably, use of antimicrobial mono-
therapy has almost systematically led to emergence of resistance for other infectious disease
pathogens, and, with few alternative treatments available or novel anthelmintics in the devel-
opmental pipeline [9], the consequences of resistance are potentially severe. In some helminth
infections of livestock (particularly sheep), resistance is so widespread and arises so frequently
that treatment-based control becomes ineffective [10, 11]. It is essential that responses to treat-
ment are monitored to identify signs of waning efficacy [8, 12–15].
The WHO has issued technical guidance and standardised protocols on monitoring the
efficacy of anthelmintic drugs using microscopy-based parasitological diagnostics [16], includ-
ing a requirement to follow up participants (SAC) 2–3 weeks after treatment to improve
homogeneity of data collection. The recommended analytical techniques—largely adapted
from methods applied in veterinary medicine where monitoring resistance in herds is com-
monplace [17, 18]—are based on measuring the average efficacy in groups of children at a pop-
ulation or community level. However, it has been argued that this is an insensitive means of
detecting the early warning signs of dwindling drug efficacy and alternative methods based on
individual participant data (IPD) [19, 20] have been proposed. Another important limitation
of the current system is the added imprecision contributed by the diagnostic methods used
(detecting eggs in feces) and the need for more sensitive molecular assays [21, 22]. In practice,
few control programmes routinely evaluate drug efficacy because of logistical complications
and the additional burden on resources of returning to treated communities before the next
round of MDA is due. Knowledge of how the anthelmintics used for MDA are performing is
thus largely based on information from clinical trials or other research studies.
The case for collating and sharing IPD has been argued recently in the context of monitor-
ing the efficacy of antischistosomal drugs, particularly praziquantel, which is the mainstay of
schistosomiasis control and elimination efforts [3, 4]. A recent landscaping systematic review
[23]—and companion to the work presented here—identified more than 20,000 IPD collected
globally since 2000. Without these IPD, it is virtually impossible to disentangle the effects of
heterogeneous study designs from more meaningful temporal or spatial trends [24]. Hence,
only the sharing, standardisation and analysis of IPD will make it possible to evaluate compre-
hensively global trends in the efficacy of anthelmintics, both against schistosomiasis and STHs.
Here we present a systematic review that identifies studies that have collected IPD on the
efficacy of benzimidazoles and other drugs used to treat STH. We evaluate heterogeneity in
study designs, geographical location and other study features and we estimate the abundance
of IPD, thus evaluating the feasibility and value of establishing a global IPD repository for
STH.
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Methods
Literature search strategy
We carried out a pilot search to estimate the volume of literature and the nature of the studies
to be examined in the landscaping exercise. We searched the MEDLINE and Embase databases
using a keyword-only search (no MeSH or EMTREE terms) and examined the references for
potential inclusion. Based on the results, we decided to exclude search terms pertaining to tri-
als, as there were some studies that were not drug trials but that did collect data from which
drug efficacy could be calculated (e.g. in studies testing diagnostic methods).
We developed detailed search strategies for the databases MEDLINE, Embase, Web of Sci-
ence, and the Cochrane Library and Cochrane Infectious Diseases Group register, compiling a
list of disease and parasite-related terms, and a list of drugs. No limits on publication date or
language were imposed within the search strategy. Where possible, we used controlled vocabu-
lary terms to filter out non-human based research. In addition, relevant references were identi-
fied from bibliographies of other published secondary analyses, including the companion
antischistosomal efficacy data landscaping review [23]. The drugs included in the search were:
albendazole, mebendazole, levamisole, ivermectin, tribendimidine, nitazoxanide, pyrantel
pamoate, and oxantel pamoate. Full details of the search strategy are given in S1 Text. The
search was last conducted on 1st July 2016. No contact with authors was attempted at this
stage, or during data extraction.
Screening and inclusion criteria
After automatic and manual de-duplication of the search results, we eliminated those pub-
lished before 2001 (as a first step to eliminating studies completed before 1st January 2000).
This cut-off was applied because older data are generally more difficult to retrieve [25], lower-
ing the likely availability for an of IPD database. Conference abstracts before 2014 were
excluded due to increasing probability of secondary reporting on studies published elsewhere.
These limits are consistent with the search conducted by Jule´ et al. [23] on studies generating
IPD on antischistosomal efficacy. We screened the titles, keywords and abstracts and/or intro-
ductions of the remaining records for inclusion. We excluded: non-human or in vitro studies;
case reports or series, and retrospective studies; reviews, secondary analyses and other non-pri-
mary research; studies in non-endemic settings; studies on costs only, coverage, perception or
other aspects of MDA programmes. Results that were not excluded by this screening were
retained for full-text reading and are itemized in S1 Dataset.
Full text articles were assessed using a checklist (see S1 Dataset). This checklist confirms
whether the data from at least some participants in a study would be suitable for estimating drug
efficacy. The checklist includes whether the study: involved diagnosis of STH infection in at least a
subset of participants; administered at least one of the drugs in the search (S1 Text) to some
infected participants, and carried out post-treatment parasitological diagnosis in some of those
participants 60 days or less after the first treatment. This cut-off is longer than the 14- to 21-day
timeframe recommended by the WHO [16]. Notwithstanding the potential diluting effect of rein-
fection on measurements made after 21 days, we adopted a more liberal cut-off to include data
that may still be informative on the efficacy of anthelmintics (with suitably adjusted statistical anal-
ysis), particularly against hookworm which can have a pre-patent period of 6 to 9 weeks [26, 27].
When we identified multiple reports from one study, all relevant publications were noted,
and one was chosen based on the amount of information found in each publication. Other
reports were used for confirmation of unclear details or further data extraction if details were
not found in the primary reference.
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Standardised data extraction
Two researchers (JBH, JB) extracted data on study: i) setting; ii) design; iii) participant
(cohort-level) characteristics; iv) type of outcomes measured and reported in the references; v)
the anthelmintic regimens used, and (where reported) vi) the numbers of individual partici-
pants treated and followed up. An estimate of the number of IPD per study arm useable for
efficacy estimation was made using the reported data (where sufficient) i.e. an estimate of the
number of participants diagnosed and tested positive, treated, and followed up within 60 days
after treatment. To facilitate standardised data extraction, we adapted a variable dictionary
developed by Jule´ et al. [23], modifying it to fit the requirements of this STH search (S2 Text).
Key terms from this dictionary are included in Table 1. We obtained native language support
for publications in Chinese, Spanish and Portuguese; data extraction from these publications
was conducted in discussion with the researchers extracting the data from the English-lan-
guage references to ensure consistency.
Estimating the number of individual participant data
We estimated the number of IPD in most instances where it was not clear how many partici-
pants’ data could be used to estimate efficacy. This often corresponded to cases where a posi-
tive diagnosis was not a criterion for treatment and where not enough data were reported to
calculate (rather than estimate) how many of the followed participants were initially positive.
The estimation method was adapted depending on the reported items in the publication.
Common methods are detailed in S3 Text; full details of the methods used for each study arm
are given in S3 dataset. The two most common examples are:
1. If a baseline (pre-treatment) prevalence of STHs caused by the three parasites of interest (A.
lumbricoides, T. trichiura and hookworm) combined was reported, this was multiplied by
the number of participants followed up, making the assumption that loss to follow up was
not dependent on parasite-specific infection status.
2. If STH prevalence was reported for each parasite separately, but with no clarification of the
prevalence of single or multiple infections, then we used the most common infection preva-
lence as the most conservative estimate of the number of participants initially positive (if
this was only given for the baseline population, then estimation method (1) also applies).
Results
Search results, geographical coverage and treatments
The literature search yielded 4,095 results after de-duplication. A total of 2,615 full-text articles
published 2001 onwards (i.e., eliminating most studies completed before 1st January 2000), or
conference abstracts from 2014 onwards, were selected from these. We screened these 2,615 by
Table 1. Glossary of key terms from the variable dictionary.
Term Definition
Study A study or trial, where a pre-defined protocol was followed for all participants, with the exception of differences
between cohorts and arms.
Cohort Groups within studies are considered as separate cohorts if at least one of these reasons applies: there were
differences in the protocol followed for different groups of participants (other than those covered by different
intervention arms); study recruitment took place in multiple distinct time periods, or participants were in different
countries; participants were in a priori defined categories which depended on participant characteristics (e.g.
diagnosis of different soil-transmitted helminth infections or other co-infections; ethnicity).
Arm Different arms of a study often correspond to different drug regimens under comparison. Study- and cohort-level
data are the same for different arms; only treatments/interventions vary. The arms are such that participants (or
clusters, as per design) could be randomized to them (though randomization was not implemented in all studies).
https://doi.org/10.1371/journal.pntd.0006053.t001
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reading the titles, abstracts/ introductions, and keywords, rejecting 2,111 clearly-ineligible arti-
cles. Articles which were not rejected at this initial screening progressed to a full-text elimina-
tion process. The 504 search results evaluated for inclusion at full-text level are detailed in S1
Dataset.
Having applied the full-text eligibility criteria, we identified 129 studies comprising 167
cohorts for inclusion in this review. Of the 375 excluded search results, 91 were primarily
excluded because they had a follow-up visit over 60 days after treatment (but fulfilled other cri-
teria); another 91 did not report assessment of infection after treatment (mainly prevalence
surveys, reports of MDA, or on other aspects of treatment such as safety). Five search results
had either an inaccessible full text or language support was not available; one of these appar-
ently fulfilled the criteria for inclusion according to the abstract only, but was excluded because
the full text could not be checked. The PRISMA flow chart summarising the identification,
screening, eligibility and inclusion process is shown in Fig 1.
From the 129 included studies, 167 eligible cohorts were partitioned out and most data
extracted at the by-cohort level; data on participant numbers and treatment regimens were
extracted per arm. The number of IPD (if given or calculable from the reported items) that
could be used for an estimate of efficacy was recorded. In 78 cohorts (comprising 129 study
arms), this number was estimated (see methods and S3 Text), and in 15 cohorts, no calculation
or estimate was made due to a lack of reported data (usually either variable follow-up time, or
no indication of prevalence of STH, especially in studies whose focus was on other parasites).
The IPD estimates given within these results therefore represent an estimate using data from
152 of the 167 cohorts, in 114 of the 129 included studies.
Included studies covered 34 of the 103 countries listed as requiring PCT by the WHO in
2015 [28], with additional studies in 5 countries (Argentina, Iran, Malaysia, Sri Lanka, Thai-
land) not indicated as requiring PCT (Fig 2). In total, we identified 85 of the 129 included stud-
ies as having a drug efficacy assessment as a primary aim of the study. A total of 23 studies
included a focus on a parasite other than those causing the three STHs of interest, including 6
with a focus on intestinal schistosomiasis.
The treatment regimens applied in the studies covered a variety of drugs and dosages.
Table 2 presents the number of studies and the associated IPD estimates for some common
drugs and regimens; full details accompany each study arm’s entry in S3 Dataset. The most
common drug administered is albendazole, with mebendazole second; of note, there are also
some large trials of chemically-unrelated compounds such as tribendimidine (an aminopheny-
lamidine) [29], several smaller studies administering ivermectin (a macrocyclic lactone) [30],
and comparatively smaller trials of nitazoxanide (a thiazolide) [31]. Diethylcarbamazine, not
included in the search strategy, was administered (and its effect on STH estimated) in one
included study [32] and one excluded study (due to there being no comparator in the list of
drugs of interest). Many additional drugs were administered to participants, most notably pra-
ziquantel, given to at least 27 cohorts (either as part of the regimens tested or when schistoso-
miasis was diagnosed).
Individual participant data and cohort characteristics
We identified 167 cohorts comprising an estimated 35,000 individual participants (diagnosed
and testing positive for STHs of interest before treatment and followed up 60 days or less after
treatment; see S3 Text for estimation methods) contributing data suitable for estimating drug
efficacy for treating STHs. The majority of cohorts comprised fewer than 150 participants,
with a heavy right skew to the distribution. 36 cohorts were estimated to comprise fewer than
50 participants eligible for efficacy estimation; WHO guidelines state a minimum of 50
Landscaping STH efficacy studies
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participants should be initially positive (per parasite) if an assessment of efficacy is to be made.
(Fig 3). Six cohorts comprised over 1,000 participants. The largest cohorts were found in stud-
ies conducted in India [29, 30], comprising 1,835 and 1,283 participants respectively. Gener-
ally, most cohorts (92 out of 166, one further study had no information in the conference
abstract in which it was reported) focused on SAC, but other demographic groups are repre-
sented as shown in Table 3. There were 9 cohorts that included pregnant women only; in the
111 cohorts recruiting any gender and reporting the breakdown, an estimate of 47% of partici-
pants were female. The age categories deemed to have been included were judged according to
Fig 1. PRISMA flow chart representing the number of items identified in the search and subsequently
screened and assessed for eligibility. The search strategy and eligibility criteria are summarised in the Methods
section and further details are given in S1 Text.
https://doi.org/10.1371/journal.pntd.0006053.g001
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the report of the study. For example, where studies were school-based, the category assigned
was SAC, reflecting the intention of the study. In some instances, school age participants were
Fig 2. Geographical coverage of studies collecting data on the efficacy of drugs for treating ascariasis, trichuriasis and
hookworm. The 39 countries with studies generating individual participant data (IPD) suitable for estimating drug efficacy are shaded
blue, with darker shades corresponding to higher estimated abundance of IPD. Five of these, with a red border, do not require
preventive chemotherapy and transmission control (PCT) for soil-transmitted helminthiases [24] (infection prevalence <20%). while
the other 34 require PCT. The 69 countries shaded in yellow had no studies identified here, and have been designated by the World
Health Organization as requiring PCT. The map was created using freely available country outline data from Natural Earth
(naturalearthdata.com).
https://doi.org/10.1371/journal.pntd.0006053.g002
Table 2. Commonly administered drug regimens from the 129 studies collecting data on the efficacy of drugs for treating ascariasis, trichuriasis
and hookworm. These regimens account for the majority (89%) of IPD suitable for efficacy estimation. Other miscellaneous drugs or regimens administered
include variations on the common mebendazole regimens, levamisole, diethylcarbamazine (DEC), and plant extracts tested for their anthelmintic effect.
There are also some treatments which were not reported in enough detail to characterise.
Drug name Dosage regimen Number of studies (cohorts)
administering this regimen
Estimated number
of IPD1
Albendazole2 400 mg single dose3
400 mg, age > 12 years / 200 mg, age < 12
years, single doses
64 (78)
6 (7)
12,574
1,130
other “albendazole-only” regimens4 25 (25) 3,740
Mebendazole2 500 mg single dose3 18 (24) 3,868
200 mg per day for 3 days 9 (11) 948
Tribendimidine various 6 (9) 2,600
Ivermectin various, including with other anthelmintics 16 (21) 2,130
Pyrantel / oxantel pamoate, or
combination of both
various, including with other anthelmintics 7 (7) 1,838
Nitazoxanide various, including with other anthelmintics 7 (9) 644
Placebo or untreated or treated with
antiprotozoan drugs only
21 (23) 1,477
1 individual participant data suitable for efficacy estimation
2 alone or with placebo, praziquantel, or antiprotozoan drugs
3 World Health Organization recommended dose for mass drug administration
4e.g. over 400 mg, and/or multiple doses
https://doi.org/10.1371/journal.pntd.0006053.t002
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reported to be outside the limits defined by the WHO [6]. In these cases, the minimum and
maximum ages reported were extracted but the category was defined as SAC.
Heterogeneity in study design, methods, and reporting
The majority of studies included a comparative aspect, defined here as either comparing differ-
ent treatment regimens or comparing treatments in different settings or cohorts (where the
comparative aspect was defined a priori). For studies comprising more than one arm, not all
studies indicated randomization between arms, and for those that did, not all reported the
method used. Similarly, blinding was not mentioned (or was not or could not have been car-
ried out) in some multi-arm studies, and for those studies in which it was, the details of who
Fig 3. Histogram and box plot showing the right-skewed distribution of the estimated number of
individual participant data (IPD) per cohort from 129 studies collecting data on the efficacy of drugs
for treating ascariasis, trichuriasis and hookworm. The median estimated cohort size is 146 with a range
from 3 to 1,835, with 15 cohorts having no estimate calculated.
https://doi.org/10.1371/journal.pntd.0006053.g003
Table 3. Number of cohorts and estimated number of individual participant data by key age groups
from 128 of the 129 studies on the efficacy of drugs for treating ascariasis, trichuriasis and hook-
worm. Age groups are assigned according to reporting of the study, which does not always coincide with
World Health Organization definitions.
Age groups included in cohort Number of cohorts Estimated number of IPD1
Pre-SAC2 6 351
Pre-SAC and SAC3 8 2,976
SAC 92 20,772
SAC and adults4 21 4,294
Adults, including pregnancy-only cohorts 23 1,680
Pre-SAC, SAC, and adults 16 4,545
1 individual participant data
2 pre-school age children, as defined or implied in each reference (usually aged 1 and < 5 years)
3 school age children, as defined or implied in each reference (usually aged 5 and < 18 years)
4 as defined or implied in each reference, usually aged > 18 years
https://doi.org/10.1371/journal.pntd.0006053.t003
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was blinded were not always given (Fig 4). Hence the risk of selection, performance, and detec-
tion biases may be difficult to quantify for many studies. Similarly, the number of patients who
were lost to follow-up was not always explicitly stated, making risk of attrition bias occasionally
troublesome to ascertain.
The majority of cohorts were followed up at 2, 3 or 4 weeks after treatment (Fig 5). Two
small cohorts had follow-ups under a week only, and 4 cohorts were first followed up at our
limit of 60 days.
All studies used microscopy (and occasionally also molecular) methods to detect and count
eggs in the feces of individual participants before and after treatment. The Kato-Katz method
(or its variations, see S1 Dataset) [33] was the most commonly used diagnostic, albeit a signifi-
cant number of studies used flotation methods such as the McMaster technique and FLOTAC
[34] and a variety of gravity- and solvent-based sedimentation methods [35]. Many studies
used multiple methods, sometimes for optimising detection of other parasites or for explicit
comparison of diagnostic performance. The techniques used in each study are summarised in
Table 4 with further details given in S1 Dataset. Participants in most cohorts were tested for
infection using a single replicate from a single stool sample before and after treatment (using
the primary diagnostic technique as assigned following the list in Jule´ et al. [23], with McMas-
ter added to this list). The most tested number of stool samples tested was 3 (before and after
treatment) and the most used number of replicates of any one technique per stool sample was
4, albeit the number of sample and replica tests was unclear in a substantial number of cohorts.
This heterogeneity is illustrated in Table 5. Participants in 12 of the 167 cohorts were also
tested for HIV, and in 20 cohorts for malaria. Reports of 37 cohorts specifically mentioned
Schistosoma mansoni as a parasite being diagnosed alongside STHs (S1 Fig).
Fig 4. Characteristics of comparative and multi-arm studies collecting data on the efficacy of drugs
for treating ascariasis, trichuriasis and hookworm. The left-hand bar shows that of 129 studies, 82 (64%)
were assessed as having a comparative aspect. For randomization (middle bar) and blinding (right-hand bar),
the bars show (from bottom to top) single arm studies; multi-arm studies in which no randomization/blinding
was reported; multi-arm studies where randomization/blinding was reported but with no details of
randomization method or of who was blinded, and finally studies where randomization/blinding was reported
and details of the method/who was blinded were given.
https://doi.org/10.1371/journal.pntd.0006053.g004
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Efficacy measures
For 96 (83%) of the 115 cohorts reporting an efficacy measure, a cure rate (CR), the proportion
of participants positive for parasites (or parasite transmission stages) before treatment who
become parasitologically negative after treatment, was reported. Many also report an egg
reduction rate (ERR), the mean number of eggs per gram of feces (EPG) after treatment
expressed as one minus the proportion of the mean EPG before treatment (and the method
recommended by the WHO [16]). Of the 89 cohorts for which an ERR was reported or calcula-
ble, 41 (46%) used an arithmetic mean (AM) for the EPG (before and after treatment), with
the remainder mostly using a geometric mean (GM), albeit with variations on how the latter
was calculated. There were 2 cohorts for which a pre- and post-treatment median EPG was
reported, and 3 for which either a log-transformed EPG or ERR calculated on log-transformed
values was given. Heterogeneity in the reported efficacy measures is illustrated in Fig 6. Within
those calculating an ERR-type measure, there is further variety in methods; two studies
reported an ERR calculated on uncured participants only (while also reporting a CR). Occa-
sionally an ERR-type measure is calculated using the mean differences between participants’
egg counts pre- and post- treatment, rather than the difference in the group mean.
Fig 5. Distribution of cohort follow-up times after treatment from 129 studies collecting data on the
efficacy of drugs for treating ascariasis, trichuriasis and hookworm. Only the first follow-up time is
included for studies involving multiple follow ups. Treatment is given on day 0. Details on how follow-up time
was calculated when a range of values were possible, are found in S2 Text. The shaded area covers 2–3
weeks after treatment, the window over which the majority of studies included here conducted their first follow-
up evaluation. Six cohorts had a variable follow-up time and are not included in the figure.
https://doi.org/10.1371/journal.pntd.0006053.g005
Landscaping STH efficacy studies
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006053 October 31, 2017 11 / 20
Discussion
We present a landscaping systematic literature review of clinical trials and related studies com-
pleted since 2000, identifying those that have collected IPD on the efficacy of drugs used to
treat the STHs ascariasis, trichuriasis and hookworm. We have estimated that there exist data
on approximately 35,000 infected participants who took part in 129 studies across 39 countries
trialling a variety of drugs and regimens, including those recommended by the WHO for the
control of STHs by PCT. We have uncovered and documented substantial heterogeneities in
the design, implementation and reporting of data from these studies. This would make a com-
prehensive evaluation of the status of anthelmintic efficacy challenging using standard meta-
analytical approaches. Yet such evaluations and status updates are becoming increasingly
important in the context of the current unprecedented scale-up of MDA for the treatment and
control of STHs as endemic countries try to reach the impending 2020 milestones [6]. To this
end, for these data to be most useful they would ideally be collated, standardised in a well-
designed shared database and pooled for the purpose of conducting IPD meta-analyses.
This study is a companion to a recent similar landscaping review of IPD on antischistoso-
mal drug efficacy [23]. Just as with antischistosomal efficacy trials, heterogeneities in study
design (e.g. the use of control cohorts, the randomization of participants or communities to
receive different treatments), implementation (e.g. follow-up times for the assessment of effi-
cacy and the demographic groups included in the study) and the methods of measuring and
reporting efficacy (e.g. CRs or ERRs using arithmetic or geometric means themselves derived
from different calculations) can all influence the efficacy outcome. This makes it extremely dif-
ficult to use all the available aggregated information to undertake comprehensive evaluations
on the global status of drug efficacy and on understanding potential geographical variation
and temporal trends.
Classical meta-analyses of antischistosomal and anti-STH efficacy generally adopt stringent
inclusion criteria to ensure data quality and limit the influence of fundamental heterogeneities
Table 4. Summary of main diagnostic methods used to detect and count eggs in the feces of partici-
pants in 129 studies collecting data on the efficacy of drugs for treating ascariasis, trichuriasis and
hookworm.
Technique Number of studies (cohorts) Estimated number of IPD1
Kato-Katz
41.7, 42, 50 mg 29 (31) 6,490
modified 8 (10) 2,697
unspecified 53 (75) 14,497
qualitative 1 (1) no estimate for this cohort
Kato
20, 25 mg 2 (2) 401
41.7 mg 2 (2) 1,002
unspecified 3 (3) 259
qualitative 1 (1) 185
McMaster
McMaster or modified McMaster 8 (20) 4,601
Concentration
Concentration (including formaldehyde) 15 (15) 2,135
Other 3 (3) 404
Unclear 4 (4) 1,948
1 individual participant data
https://doi.org/10.1371/journal.pntd.0006053.t004
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in study design. Often this means that only data from randomized controlled trials are consid-
ered for analysis [36–38], severely restricting the availability of data and failing to circumvent
problems associated with other heterogeneities (such as variable follow-up times; diagnostic
methods; approaches to efficacy evaluation and recruited demographic groups). More relaxed
Table 5. Variation in samples and repeats used with the Kato-Katz technique. Number of cohorts (and number of estimated individual participant data in
parentheses) from the subset comprising 91 studies collecting data on the efficacy of drugs for treating the soil-transmitted helminthiases ascariasis, trichuria-
sis and hookworm in which infection was diagnosed, primarily using a Kato-Katz method, before (a) or after (b) treatment by performing X × Y
(samples × replicates) egg counts.
a) Diagnosis Kato-Katz: replicate slides
1 2 3 4 unclear
Samples 1 16 (2,526) 23 (3,969) 5 (1,189) 1 (529) 31 (6,540)
2 0 14 (3,224) 1 (134) 0 1 (107)
3 2 (36) 0 0 0 3 (113)
unclear 0 0 0 0 19 (5,318)
b) Follow-up Kato-Katz: replicate slides
1 2 3 4 unclear
Samples 1 15 (3,113) 23 (3,157) 6 (2,775) 1 (529) 27 (6,262)
2 1 (97) 13 (3,210) 4 (746) 3 (505) 1 (107)
3 3 (178) 0 0 0 5 (364)
unclear 0 0 0 0 14 (2,642)
https://doi.org/10.1371/journal.pntd.0006053.t005
Fig 6. Heterogeneity in efficacy measures reported from cohorts collecting data on the efficacy of
drugs for treating ascariasis, trichuriasis and hookworm. Bar (a) shows the total number of cohorts for
which measuring drug efficacy against those STHs with a parasitological measure as an outcome was a
primary aim. Bar (b) shows the number of cohorts reporting any efficacy measure or appropriate pre- and
post-treatment data, divided from left to right into: egg reduction rate (ERR) only; ERR and cure rate (CR), and
CR only. Bar (c) shows the total number of cohorts reporting ERR or a pre- and post-treatment measure of
intensity, divided from left to right into those: reporting medians; calculating ERR using or reporting log-
transformed values; using an arithmetic mean (AM) or both an AM and a geometric mean (GM); using a GM
only with a method given; using a GM only with unreported method, and using an unclear measure of central
tendency.
https://doi.org/10.1371/journal.pntd.0006053.g006
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eligibility criteria combined with contemporary meta-analytical approaches [39, 40] can
increase the available evidence base and help to mitigate the influence of study heterogeneities.
Nonetheless even these approaches remain fundamentally limited by the aggregate nature of
data reporting.
The benefit of IPD is that both individual- and study-level variables can be incorporated
directly into statistical analyses while also accounting for unmeasured or unmeasurable ran-
dom variation among studies, cohorts and individual participants. This permits not only
detailed investigation of the influence of individual participant variables on drug responses
(e.g. age, sex, time of follow up and co-infection status) but also residual (unexplained) varia-
tion among individual drug responses [20, 41, 42]. Such individual level meta-analyses offer
greater sensitivity than their aggregate level counterparts to identify suspicious or atypical
drug responses [19] that are potentially indicative of, for example, emerging drug resistance,
suboptimal dosing in particular sub-populations, medicine quality issues or drug interactions
and warrant further follow-up investigation. In particular, variation in parasite drug suscepti-
bility (possibly genetically mediated) cannot be included in such individual patient (host) anal-
yses and thus molecular [43] follow-up analyses of parasitological samples from individuals
exhibiting atypical responses would be informative.
Notwithstanding the potential benefits of IPD to identifying and responding to atypical
drug responses, more research must be done to differentiate between truly suspicious
responses and naturally expected levels of person-to-person variation. Such variation may be
driven by both host [19, 42] and parasite factors [44] (including the more refractory nature of
some STH species, particularly T. trichiura and to a lesser extent hookworm species [36]) but
may be dominated by error inherent to parasitological (egg count-based) diagnostics [45–47].
Underlying drivers may become somewhat unmasked as more accurate molecular-based diag-
nostics [21, 22] become more commonplace. It will be important to define distributions of
responses based on both parasitological and new molecular diagnostic approaches in popula-
tions infected with treatment-naïve parasites [42] to serve as a comparative reference to
response distributions in populations exposed to multiple rounds of MDA under the PCT
strategy [19]. Equally important, statistical approaches should properly integrate variability in
diagnostics (particularly the high variability associated with parasitological diagnostics) into
estimates of efficacies with robust associated uncertainty to avoid ‘false alarms’ from spuriously
atypical point estimates [20, 42].
Currently there is no incontrovertible evidence of benzimidazole resistance in humans [8,
13, 15]. Some studies have observed poor responses in communities under long-term MDA
[48, 49] although no genetic basis for these responses was found [50]. Nevertheless, it would be
poor public health practice to ignore the possibility that resistance could emerge, especially
since there are few alternatives available now and there remain significant challenges to incen-
tivising commercial investment in anthelmintic drug discovery and development [51, 52].
This means that the effectiveness and cost-effectiveness of PCT [7] is extremely vulnerable to
reductions in drug efficacy and there is consensus on the importance of its robust monitoring
and evaluation [8, 12–15].
The WHO recommends that assessment of drug efficacy should be conducted in school-
children 14 to 21 days after treatment [16]. This presents logistical and resource challenges to
programmes that must return to communities shortly after treatment rounds have been dis-
tributed and before the next round of MDA is due. Yet the risks posed by reduced efficacy to
the sustainability and cost-effectiveness of PCT programs mean that efficacy assessment
should be undertaken, at least in sentinel sites. The WHO guidelines [16] on standardizing the
assessment of anthelmintic efficacy will hopefully increase the homogeneity of future efficacy
studies. We suggest that guidance on conducting analyses using IPD could complement the
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existing recommended (population-based) protocols and that these should include detailed
instruction on robust quantification and reporting of associated estimates of uncertainty.
Maximizing the potential of IPD for global monitoring and evaluation requires broad stake-
holder commitment to data sharing, and a framework that protects the rights of patients, data
contributors and data users, and ultimately serves the purpose of increasing knowledge and
improving health. The WHO has issued three guiding principles for the operation of data shar-
ing during public health emergencies [53], with adapted operating principles suggested for a
global-health orientated approach [54]: an explicit ethical and legal framework governing data
collection and use; the publication of results from additional analyses in a reasonable time-
frame, and the development and publication of terms of data use by platform operators. Exam-
ples of data sharing platforms include Flu Informed Decisions (FluID, https://extranet.who.
int/fluid/) and the Worldwide Antimalarial Resistance Network (WWARN, www.wwarn.org).
We have focused here on studies generating IPD that could be used to estimate the efficacy
of drugs used to treat STHs, following the general approach of the preceding companion paper
that identified > 20,000 IPD suitable for quantifying antischistosomal efficacy [23]. The over-
lapping geographical epidemiology [55] and the closely related methods of quantitative diag-
nosis (counting eggs in feces, or urine for urogenital schistosomiasis) and methods for efficacy
calculation (e.g. ERRs [16]) mean that schistosomiasis and STH would be natural companions
in any future shared database. Indeed, many of the studies identified in our search diagnosed
and administered treatment for both diseases (S1 Fig, S1 Dataset). Moreover, four of the eligi-
ble studies identified by Jule´ et al. [23] which were also eligible for inclusion (and included) in
this study were not identified by the STH-specific literature search because there were no rele-
vant search terms in the title, abstract, keywords, or controlled vocabulary. This illustrates the
possibility of retrieving STH-relevant data from studies on epidemiologically-related
infections.
Like Jule´ et al. [23], we included all studies with a follow up within 60 days of drug adminis-
tration. This includes a wide range of follow ups, many outside of the 2- to 3-week optimum
window recommended by the WHO [16] (Fig 5). However, the inclusion of data collected at
various follow up times, including less than 1 week when eggs will not yet have been
completely cleared from the stool [56, 57] and efficacy will be underestimated, would provide
comprehensive information on the dynamics of the drug response, including initial clearance
dynamics and longer-term reinfection or repopulation. The effect of follow up time (and other
covariates) could be incorporated at the analysis stage offering a means to compare data col-
lected by heterogeneous study designs [42]. Follow up time is a key variable in the interpreta-
tion and estimation of drug efficacy and while we wholly concord with WHO’s
recommendation to standardize future study designs [16], the reality of past studies is of het-
erogeneity (in this and other important variables). Rather than discarding data from such stud-
ies, we suggest collation of IPD and suitable adjustment for study design at the analysis stage.
The true availability of IPD on drug efficacy against STH is likely to be even greater than
the 35,000 participants estimated here. We adopted a conservative approach to the estimation
of the abundance of IPD in the 78 cohorts where it was not explicit, and did not calculate an
estimate from a further 15, so that we are likely to have underestimated the true value. We did
not estimate the abundance of IPD from all studies on pregnant women because it was fre-
quently unclear how many individuals were followed up before the 60-day cut-off; recruitment
and treatment tended to be carried out during a wider temporal window (second trimester
onwards) and the first follow-up stool sample was often taken at delivery or at an ante-natal
visit yielding a variety of follow-up times that often exceeded our 60-day cut-off. A meaningful
estimation of pregnant participants whose data could contribute to an efficacy calculation
would require an indication of the distribution of follow-up time.
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Our estimated abundance of IPD is also likely to represent an underestimate because our
search was limited to four databases in which the majority of the literature is published in
English. We did not search the regional CNKI (China National Knowledge Infrastructure) or
LILACS (Latin American and Caribbean Health Sciences Literature) databases [58], which
may contain relevant literature from endemic areas. Our search did yield a number of non-
English language results; we noted that two of these studies originally published in Chinese
were published 5 years later in English-language journals. Hence, although some studies may
ultimately appear in English, there may be a substantial delay between the original publication
and the translated version. One study conducted in Uzbekistan [59], was not translated from
Russian and its inclusion in the final analysis would have constituted the sole representative of
the central Asian region. A further source of STH treatment efficacy data may be found in
studies focused on other diseases; the key example is schistosomiasis, but studies treating other
helminthiases (especially strongyloidiasis, often treated with ivermectin) or intestinal proto-
zoan infections may also yield suitable data (many studies identified here treated a range of
parasitic diseases). Finally, we note that only published literature was searched, most of which
was found through the search of online databases; grey literature and other sources of study
information could not be retrieved with the methods used.
Conclusions
Published clinical trials on the efficacy of the drugs used to treat STH are highly variable in
their design, implementation, and reporting of results. This heterogeneous landscape, which is
common with antischistosomal drug trials, presents substantial challenges to conducting
meta-analyses aiming to evaluate, in a comprehensive manner, the performance of anthelmin-
tics drugs in the context of burgeoning MDA programmes in an attempt to meet the WHO
2020 goals of STH treatment coverage globally. Yet, together, these trials and other studies pro-
vide an abundance of IPD that, if extracted and appropriately analysed, could minimise the
confounding associated with aggregate data and greatly improve the capacity of the global
health community to understand naturally-occurring individual variation in responses and
distinguish these from atypical or truly suspicious drug responses, potentially indicative of
emerging drug resistance. We believe that this capability presents a compelling argument to
embrace a data sharing philosophy within the STH, schistosomiasis and wider NTD commu-
nities, to develop a shared IPD database and to adopt rigorous individual-level meta-analysis
approaches undertaken by conglomerates of stakeholders and for the benefit of public health
end-users and health policy decision makers.
Supporting information
S1 Text. Literature search strategy.
(DOCX)
S2 Text. Variable dictionary.
(DOC)
S3 Text. Estimating number of individual participant data.
(DOCX)
S4 Text. PRISMA checklist.
(DOC)
S1 Fig. Number of cohorts from studies collecting data on the efficacy of drugs for treating
ascariasis, trichuriasis and hookworm, including participants with coinfections at time of
Landscaping STH efficacy studies
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006053 October 31, 2017 16 / 20
treatment. Abbreviations from left to right: S. mansoni, Schistosoma mansoni; S. stercoralis,
Strongyloides stercoralis; H. nana, Hymenolepis nana; E. vermicularis, Enterobius vermicularis;
Taenia spp., Taenia species; HIV, human immunodeficieny virus.
(TIF)
S1 Dataset. Screening results.
(XLSX)
S2 Dataset. Cohort-level data.
(XLSX)
S3 Dataset. Arm-level data.
(XLSX)
Acknowledgments
Our thanks go to Ms Han Fu and Dr Zulma Cucunuba´ (Department of Infectious Disease Epi-
demiology, Imperial College London) for translation assistance (Chinese and Spanish, respec-
tively) and discussions on study design. Ms Jacqueline Cousins (St Mary’s campus Library,
Imperial College London) provided extensive search advice and Dr Vittoria Lutje advised on
construction of a search strategy and performed the search of the Cochrane Infectious Diseases
Group register. We also thank Dr Antonio Montresor (Department of Control of Neglected
Tropical Diseases, World Health Organization) and Ms Julia Dunn (Department of Infectious
Disease Epidemiology and London Centre for Neglected Tropical Disease Research, Imperial
College London) for comments on the manuscript.
Author Contributions
Conceptualization: Julia B. Halder, Martin Walker.
Data curation: Julia B. Halder, Joanne Benton, Ame´lie M. Jule´.
Formal analysis: Julia B. Halder, Joanne Benton, Ame´lie M. Jule´.
Methodology: Julia B. Halder, Ame´lie M. Jule´, Martin Walker.
Supervision: Marı´a-Gloria Basa´ñez, Martin Walker.
Writing – original draft: Julia B. Halder, Martin Walker.
Writing – review & editing: Julia B. Halder, Joanne Benton, Ame´lie M. Jule´, Phillipe J. Gue´rin,
Piero L. Olliaro, Marı´a-Gloria Basa´ñez, Martin Walker.
References
1. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national
incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a sys-
tematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016; 388(10053):1545–602.
https://doi.org/10.1016/S0140-6736(16)31678-6 PMID: 27733282; PubMed Central PMCID:
PMCPMC5055577.
2. Bethony J, Brooker S, Albonico M, Geiger SM, Loukas A, Diemert D, et al. Soil-transmitted helminth
infections: ascariasis, trichuriasis, and hookworm. Lancet. 2006; 367(9521):1521–32. https://doi.org/
10.1016/S0140-6736(06)68653-4 PMID: 16679166.
3. World Health Organization. Preventive chemotherapy in human helminthiases. Geneva, Switzerland:
World Health Organization, 2006.
4. World Health Organization. Accelerating work to overcome the global impact of neglected tropical 13.
diseases–a roadmap for implementation executive summary. Genva, Switzerland: World Health Orga-
nization, 2012 WHO/HTM/NTD/2012.1.
Landscaping STH efficacy studies
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006053 October 31, 2017 17 / 20
5. London Declaration on Neglected Tropical Diseases. Ending the neglect and reaching 2020 goals.
2012.
6. World Health Organization. Update on the global status of implementation of preventive chemotherapy
(PC). Geneva, Switzerland: World Health Organization, 2017.
7. Turner HC, Truscott JE, Fleming FM, Hollingsworth TD, Brooker SJ, Anderson RM. Cost-effectiveness
of scaling up mass drug administration for the control of soil-transmitted helminths: a comparison of
cost function and constant costs analyses. Lancet Infect Dis. 2016; 16(7):838–46. https://doi.org/10.
1016/S1473-3099(15)00268-6 PMID: 26897109.
8. Webster JP, Molyneux DH, Hotez PJ, Fenwick A. The contribution of mass drug administration to global
health: past, present and future. Philos Trans R Soc Lond B Biol Sci. 2014; 369(1645):20130434.
https://doi.org/10.1098/rstb.2013.0434 PMID: 24821920; PubMed Central PMCID: PMCPMC4024227.
9. Geary TG, Sakanari JA, Caffrey CR. Anthelmintic drug discovery: into the future. J Parasitol. 2015; 101
(2):125–33. https://doi.org/10.1645/14-703.1 PMID: 25584662.
10. Kaplan RM, Vidyashankar AN. An inconvenient truth: global worming and anthelmintic resistance. Vet
Parasitol. 2012; 186(1–2):70–8. https://doi.org/10.1016/j.vetpar.2011.11.048 PMID: 22154968.
11. Redman E, Whitelaw F, Tait A, Burgess C, Bartley Y, Skuce PJ, et al. The emergence of resistance to
the benzimidazole anthlemintics in parasitic nematodes of livestock is characterised by multiple inde-
pendent hard and soft selective sweeps. PLoS Negl Trop Dis. 2015; 9(2):e0003494. https://doi.org/10.
1371/journal.pntd.0003494 PMID: 25658086; PubMed Central PMCID: PMCPMC4319741.
12. Albonico M, Engels D, Savioli L. Monitoring drug efficacy and early detection of drug resistance in
human soil-transmitted nematodes: a pressing public health agenda for helminth control. Int J Parasitol.
2004; 34(11):1205–10. https://doi.org/10.1016/j.ijpara.2004.08.001 PMID: 15491582.
13. Vercruysse J, Albonico M, Behnke JM, Kotze AC, Prichard RK, McCarthy JS, et al. Is anthelmintic resis-
tance a concern for the control of human soil-transmitted helminths? Int J Parasitol Drugs Drug Resist.
2011; 1(1):14–27. https://doi.org/10.1016/j.ijpddr.2011.09.002 PMID: 24533260; PubMed Central
PMCID: PMCPMC3913213.
14. Basa´ñez MG, McCarthy JS, French MD, Yang GJ, Walker M, Gambhir M, et al. A research agenda for
helminth diseases of humans: modelling for control and elimination. PLoS Negl Trop Dis. 2012; 6(4):
e1548. https://doi.org/10.1371/journal.pntd.0001548 PMID: 22545162; PubMed Central PMCID:
PMCPMC3335861.
15. Vercruysse J, Levecke B, Prichard R. Human soil-transmitted helminths: implications of mass drug
administration. Curr Opin Infect Dis. 2012; 25(6):703–8. https://doi.org/10.1097/QCO.
0b013e328358993a PMID: 22964945.
16. World Health Organization. Assessing the Efficacy of Anthelminthic Drugs Against Schistosomiasis and
Soil-Transmitted Helminthiases. Geneva, Switzerland: World Health Organization, 2013.
17. Coles GC, Jackson F, Pomroy WE, Prichard RK, von Samson-Himmelstjerna G, Silvestre A, et al. The
detection of anthelmintic resistance in nematodes of veterinary importance. Vet Parasitol. 2006; 136(3–
4):167–85. https://doi.org/10.1016/j.vetpar.2005.11.019 PMID: 16427201.
18. Rose H, Rinaldi L, Bosco A, Mavrot F, de Waal T, Skuce P, et al. Widespread anthelmintic resistance in
European farmed ruminants: a systematic review. Vet Rec. 2015; 176(21):546. https://doi.org/10.1136/
vr.102982 PMID: 25762583.
19. Crellen T, Walker M, Lamberton PH, Kabatereine NB, Tukahebwa EM, Cotton JA, et al. Reduced Effi-
cacy of Praziquantel Against Schistosoma mansoni Is Associated With Multiple Rounds of Mass Drug
Administration. Clin Infect Dis. 2016; 63(9):1151–9. https://doi.org/10.1093/cid/ciw506 PMID:
27470241; PubMed Central PMCID: PMCPMC5064161.
20. Walker M, Churcher TS, Basa´ñez MG. Models for measuring anthelmintic drug efficacy for parasitolo-
gists. Trends Parasitol. 2014; 30(11):528–37. https://doi.org/10.1016/j.pt.2014.08.004 PMID:
25217844.
21. Easton AV, Oliveira RG, O’Connell EM, Kepha S, Mwandawiro CS, Njenga SM, et al. Multi-parallel
qPCR provides increased sensitivity and diagnostic breadth for gastrointestinal parasites of humans:
field-based inferences on the impact of mass deworming. Parasit Vectors. 2016; 9:38. https://doi.org/
10.1186/s13071-016-1314-y PMID: 26813411; PubMed Central PMCID: PMCPMC4729172.
22. Easton AV, Oliveira RG, Walker M, O’Connell EM, Njenga SM, Mwandawiro CS, et al. Sources of vari-
ability in the measurement of Ascaris lumbricoides infection intensity by Kato-Katz and qPCR. Parasit
Vectors. 2017; 10(1):256. https://doi.org/10.1186/s13071-017-2164-y PMID: 28545561; PubMed Cen-
tral PMCID: PMCPMC5445470.
23. Jule´ AM, Vaillant M, Lang TA, Gue´rin PJ, Olliaro PL. The Schistosomiasis Clinical Trials Landscape: A
Systematic Review of Antischistosomal Treatment Efficacy Studies and a Case for Sharing Individual
Participant-Level Data (IPD). PLoS Negl Trop Dis. 2016; 10(6):e0004784. https://doi.org/10.1371/
journal.pntd.0004784 PMID: 27347678; PubMed Central PMCID: PMCPMC4922574.
Landscaping STH efficacy studies
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006053 October 31, 2017 18 / 20
24. Jule´ AM, Halder JB, Vaillant M, Basa´ñez MG, Lang TA, Walker M, et al. Systematic review of antischis-
tosomal treatment efficacy studies and the significance of individual-level participant data for meta-anal-
yses. Am J Trop Med Hyg. 2016; 95(S5):371.
25. Vines TH, Albert AY, Andrew RL, De´barre F, Bock DG, Franklin MT, et al. The availability of research
data declines rapidly with article age. Curr Biol. 2014; 24(1):94–7. https://doi.org/10.1016/j.cub.2013.
11.014 PMID: 24361065.
26. Cline BL, Little MD, Bartholomew RK, Halsey NA. Larvicidal activity of albendazole against Necator
americanus in human volunteers. Am J Trop Med Hyg. 1984; 33(3):387–94. PMID: 6731670.
27. Maxwell C, Hussain R, Nutman TB, Poindexter RW, Little MD, Schad GA, et al. The clinical and immu-
nologic responses of normal human volunteers to low dose hookworm (Necator americanus) infection.
Am J Trop Med Hyg. 1987; 37(1):126–34. PMID: 3605493.
28. World Health Organization. Number of children (Pre-SAC and SAC) requiring preventive chemotherapy
for soil-transmitted helminthiases Geneva, Switzerland: World Health Organization; 2015. Available
from: http://apps.who.int/neglected_diseases/ntddata/sth/sth.html.
29. Zhang JH, Xiao SH, Wu ZX, Qiu DC, Wang SH, Wang SQ, et al. [Tribendimidine enteric coated tablet in
treatment of 1,292 cases with intestinal nematode infection—a phase IV clinical trial]. Zhongguo Ji
Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2008; 26(1):6–9. PMID: 18637576.
30. Ndyomugyenyi R, Kabatereine N, Olsen A, Magnussen P. Efficacy of ivermectin and albendazole alone
and in combination for treatment of soil-transmitted helminths in pregnancy and adverse events: a ran-
domized open label controlled intervention trial in Masindi district, western Uganda. Am J Trop Med
Hyg. 2008; 79(6):856–63. PMID: 19052293.
31. Speich B, Ame SM, Ali SM, Alles R, Hattendorf J, Utzinger J, et al. Efficacy and safety of nitazoxanide,
albendazole, and nitazoxanide-albendazole against Trichuris trichiura infection: a randomized con-
trolled trial. PLoS Negl Trop Dis. 2012; 6(6):e1685. https://doi.org/10.1371/journal.pntd.0001685 PMID:
22679525; PubMed Central PMCID: PMCPMC3367984.
32. Sunish IP, Rajendran R, Munirathinam A, Kalimuthu M, Kumar VA, Nagaraj J, et al. Impact on preva-
lence of intestinal helminth infection in school children administered with seven annual rounds of diethyl
carbamazine (DEC) with albendazole. Indian J Med Res. 2015; 141(3):330–9. PMID: 25963494;
PubMed Central PMCID: PMCPMC4442331.
33. World Health Organization. Basic Laboratory Methods in Medical Parasitology. Geneva, Switzerland:
World Health Organization, 1991.
34. Cringoli G. FLOTAC, a novel apparatus for a multivalent faecal egg count technique. Parassitologia.
2006; 48(3):381–4. PMID: 17176947.
35. Goodman D, Haji HJ, Bickle QD, Stoltzfus RJ, Tielsch JM, Ramsan M, et al. A comparison of methods
for detecting the eggs of Ascaris, Trichuris, and hookworm in infant stool, and the epidemiology of infec-
tion in Zanzibari infants. Am J Trop Med Hyg. 2007; 76(4):725–31. PMID: 17426179.
36. Keiser J, Utzinger J. Efficacy of current drugs against soil-transmitted helminth infections: systematic
review and meta-analysis. JAMA. 2008; 299(16):1937–48. https://doi.org/10.1001/jama.299.16.1937
PMID: 18430913.
37. Danso-Appiah A, Olliaro PL, Donegan S, Sinclair D, Utzinger J. Drugs for treating Schistosoma man-
soni infection. Cochrane Database Syst Rev. 2013;(2):CD000528. https://doi.org/10.1002/14651858.
CD000528.pub2 PMID: 23450530.
38. Kramer CV, Zhang F, Sinclair D, Olliaro PL. Drugs for treating urinary schistosomiasis. Cochrane Data-
base Syst Rev. 2014;(8):CD000053. https://doi.org/10.1002/14651858.CD000053.pub3 PMID:
25099517; PubMed Central PMCID: PMCPMC4447116.
39. Zwang J, Olliaro P. Efficacy and safety of praziquantel 40 mg/kg in preschool-aged and school-aged
children: a meta-analysis. Parasit Vectors. 2017; 10(1):47. https://doi.org/10.1186/s13071-016-1958-7
PMID: 28126024; PubMed Central PMCID: PMCPMC5270314.
40. Zwang J, Olliaro PL. Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistoso-
miasis-a meta-analysis of comparative and non-comparative clinical trials. PLoS Negl Trop Dis. 2014; 8
(11):e3286. https://doi.org/10.1371/journal.pntd.0003286 PMID: 25412105; PubMed Central PMCID:
PMCPMC4238982.
41. Olliaro PL, Vaillant M, Diawara A, Coulibaly JT, Garba A, Keiser J, et al. Toward Measuring Schisto-
soma Response to Praziquantel Treatment with Appropriate Descriptors of Egg Excretion. PLoS Negl
Trop Dis. 2015; 9(6):e0003821. https://doi.org/10.1371/journal.pntd.0003821 PMID: 26086551;
PubMed Central PMCID: PMCPMC4473103.
42. Walker M, Mabud TS, Olliaro PL, Coulibaly JT, King CH, Raso G, et al. New approaches to measuring
anthelminthic drug efficacy: parasitological responses of childhood schistosome infections to treatment
with praziquantel. Parasit Vectors. 2016; 9:41. https://doi.org/10.1186/s13071-016-1312-0 PMID:
26813154; PubMed Central PMCID: PMCPMC4728951.
Landscaping STH efficacy studies
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006053 October 31, 2017 19 / 20
43. Kotze AC, Hunt PW, Skuce P, von Samson-Himmelstjerna G, Martin RJ, Sager H, et al. Recent
advances in candidate-gene and whole-genome approaches to the discovery of anthelmintic resistance
markers and the description of drug/receptor interactions. Int J Parasitol Drugs Drug Resist. 2014; 4
(3):164–84. https://doi.org/10.1016/j.ijpddr.2014.07.007 PMID: 25516826; PubMed Central PMCID:
PMCPMC4266812.
44. Diawara A, Halpenny CM, Churcher TS, Mwandawiro C, Kihara J, Kaplan RM, et al. Association
between response to albendazole treatment and beta-tubulin genotype frequencies in soil-transmitted
helminths. PLoS Negl Trop Dis. 2013; 7(5):e2247. https://doi.org/10.1371/journal.pntd.0002247 PMID:
23738029; PubMed Central PMCID: PMCPMC3667785.
45. Hall A. Quantitative variability of nematode egg counts in faeces: a study among rural Kenyans. Trans
R Soc Trop Med Hyg. 1981; 75(5):682–7. PMID: 7330922.
46. Anderson RM, Schad GA. Hookworm burdens and faecal egg counts: an analysis of the biological
basis of variation. Trans R Soc Trop Med Hyg. 1985; 79(6):812–25. PMID: 3832493.
47. Booth M, Vounatsou P, N’Goran E K, Tanner M, Utzinger J. The influence of sampling effort and the
performance of the Kato-Katz technique in diagnosing Schistosoma mansoni and hookworm co-infec-
tions in rural Cote d’Ivoire. Parasitology. 2003; 127(Pt 6):525–31. PMID: 14700188.
48. Albonico M, Bickle Q, Ramsan M, Montresor A, Savioli L, Taylor M. Efficacy of mebendazole and levam-
isole alone or in combination against intestinal nematode infections after repeated targeted mebenda-
zole treatment in Zanzibar. Bull World Health Organ. 2003; 81(5):343–52. PMID: 12856052; PubMed
Central PMCID: PMCPMC2572452.
49. Albonico M, Ramsan M, Wright V, Jape K, Haji HJ, Taylor M, et al. Soil-transmitted nematode infections
and mebendazole treatment in Mafia Island schoolchildren. Ann Trop Med Parasitol. 2002; 96(7):717–
26. https://doi.org/10.1179/000349802125001942 PMID: 12537633.
50. Albonico M, Wright V, Bickle Q. Molecular analysis of the beta-tubulin gene of human hookworms as a
basis for possible benzimidazole resistance on Pemba Island. Mol Biochem Parasitol. 2004; 134
(2):281–4. https://doi.org/10.1016/j.molbiopara.2003.12.008 PMID: 15003848.
51. Dimitri N. R&D incentives for neglected diseases. PLoS One. 2012; 7(12):e50835. https://doi.org/10.
1371/journal.pone.0050835 PMID: 23284648; PubMed Central PMCID: PMCPMC3526606.
52. Mueller-Langer F. Neglected infectious diseases: are push and pull incentive mechanisms suitable for
promoting drug development research? Health Econ Policy Law. 2013; 8(2):185–208. https://doi.org/
10.1017/S1744133112000321 PMID: 23343639; PubMed Central PMCID: PMCPMC3592259.
53. Modjarrad K, Moorthy VS, Millett P, Gsell PS, Roth C, Kieny MP. Developing Global Norms for Sharing
Data and Results during Public Health Emergencies. PLoS Med. 2016; 13(1):e1001935. https://doi.org/
10.1371/journal.pmed.1001935 PMID: 26731342; PubMed Central PMCID: PMCPMC4701443.
54. Moorthy VS, Roth C, Olliaro P, Dye C, Kieny MP. Best practices for sharing information through data
platforms: establishing the principles. Bull World Health Organ. 2016; 94(4):234–A. https://doi.org/10.
2471/BLT.16.172882 PMID: 27034512; PubMed Central PMCID: PMCPMC4794314.
55. Global Atlas of Helminth Infections. Global Atlas of Helminth Infections 2017. Available from: http://
www.thiswormyworld.org/.
56. Forrester JE, Scott ME. Measurement of Ascaris lumbricoides infection intensity and the dynamics of
expulsion following treatment with mebendazole. Parasitology. 1990; 100 Pt 2:303–8. PMID: 2345663.
57. Bundy DA, Thompson DE, Cooper ES, Blanchard J. Rate of expulsion of Trichuris trichiura with multiple
and single dose regimens of albendazole. Trans R Soc Trop Med Hyg. 1985; 79(5):641–4. PMID:
4095746.
58. Williams JR, Bo´rquez A, Basa´ñez MG. Hispanic Latin America, Spain and the Spanish-speaking Carib-
bean: a rich source of reference material for public health, epidemiology and tropical medicine. Emerg
Themes Epidemiol. 2008; 5:17. https://doi.org/10.1186/1742-7622-5-17 PMID: 19243576; PubMed
Central PMCID: PMCPMC2584035.
59. Davis NA, Giiasov Kh Z, Islamova Zh I, Tuĭchiev LN, Parpieva NN, Belotserkovets VG, et al. [Evaluation
of the efficacy of antiparasitic drugs in the treatment of concurrent parasitic diseases in patients with
HIV infection and in those with pulmonary tuberculosis]. Med Parazitol (Mosk). 2013;(4):24–7. PMID:
24640127.
Landscaping STH efficacy studies
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006053 October 31, 2017 20 / 20
